Literature DB >> 11578724

Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome.

R J Myerson1, F Kong, E H Birnbaum, J W Fleshman, I J Kodner, J Picus, G A Ratkin, T E Read, B J Walz.   

Abstract

BACKGROUND AND
PURPOSE: In recent years, treatment with combined chemotherapy and radiation has become the standard of care for epidermoid carcinoma of the anus. However, optimal radiotherapy techniques and doses are not well established.
MATERIALS AND METHODS: During the period 1975-1997, 106 patients with epidermoid carcinoma of the anal canal underwent radiation therapy. Treatment policies evolved from radiation therapy alone or with surgery, to combined chemotherapy and radiation followed by surgery, to combined chemotherapy and radiation.
RESULTS: Overall 74% of patients were NED (no evidence of disease) at last follow-up. The most important clinical correlate with ultimate freedom from disease (includes the contribution of salvage surgery) was extent of disease. The 5-year ultimate freedom from disease was 87+/-5% for T1/T2N0, 78+/-10% for T3N0 (15% salvaged by surgery), and 43+/-10% for either T4N0 or any N+ lesions (P<0.001, Tarone-Ware). There was no difference between planned vs. expectant surgery (5-year ultimate NED: 67+/-11% planned surgery vs. 73+/-5% expectant surgery). The most important correlate with late toxicity was a history of major pelvic surgery (surgical vs. non-surgical group: P=0.013, Fisher's exact test, two-tailed summation). Thirty-three additional malignancies have been seen in 26 patients. The most common additional malignancies were gynecologic (nine cases), head and neck (six cases), and lung cancer (five cases).
CONCLUSIONS: For T1/T2N0 disease, moderate doses of radiation combined with chemotherapy provided adequate treatment. T4N0 and N+ lesions are the most appropriate candidates for investigational protocols evaluating dose intensification. T3N0 tumors may also be appropriate for investigation; however, dose intensification may ultimately prove counterproductive if the cure rate is not improved and salvage surgery is rendered more difficult. The volume of irradiated small bowel should be minimized for patients who have a past history of major pelvic surgery or who (because of locally advanced tumors) may need salvage surgery in the future. Because of the occurrence of additional malignancy, patients with anal cancer should receive general oncologic screening in long-term follow-up.

Entities:  

Mesh:

Year:  2001        PMID: 11578724     DOI: 10.1016/s0167-8140(01)00404-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

1.  Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy.

Authors:  Arnaud Hocquelet; Thibaut Auriac; Cynthia Perier; Clarisse Dromain; Marie Meyer; Jean-Baptiste Pinaquy; Alban Denys; Hervé Trillaud; Baudouin Denis De Senneville; Véronique Vendrely
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

2.  Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy.

Authors:  José Luis López Guerra; Antonio José Lozano; Joan Pera; Cristina Gutiérrez; María Cambray; Ferran Ferrer; Ferran Guedea
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

3.  [Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience].

Authors:  M F Osti; L Agolli; C Scaringi; S Bracci; G Minniti; R Maurizi Enrici
Journal:  Radiol Med       Date:  2012-11-26       Impact factor: 3.469

Review 4.  New approach to anal cancer: individualized therapy based on sentinel lymph node biopsy.

Authors:  Paola De Nardi; Michele Carvello; Carlo Staudacher
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

5.  Sentinel lymph node in patients with rectal cancer invading the anal canal.

Authors:  D C Damin; G C Tolfo; M A Rosito; B L Spiro; L M Kliemann
Journal:  Tech Coloproctol       Date:  2010-04-28       Impact factor: 3.781

6.  Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival.

Authors:  Letizia Deantonio; Maria Elisa Milia; Tiziana Cena; Gianmauro Sacchetti; Carola Perotti; Marco Brambilla; Lucia Turri; Marco Krengli
Journal:  Radiol Med       Date:  2015-07-01       Impact factor: 3.469

7.  The role of MRI in the assessment of the local status of anal carcinomas and in their management.

Authors:  É Jederán; J Lővey; Z Szentirmai; E Hitre; G Léránt; K Horváth; M Gődény
Journal:  Pathol Oncol Res       Date:  2014-10-30       Impact factor: 3.201

8.  Surgical salvage therapy of anal cancer.

Authors:  Yue-Kui Bai; Wen-Lan Cao; Ji-Dong Gao; Jun Liang; Yong-Fu Shao
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

9.  Prognostic factors for squamous cell cancer of the anal canal.

Authors:  Prajnan Das; Christopher H Crane; Cathy Eng; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2008-01

10.  Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.

Authors:  A A Melcher; D Sebag-Montefiore
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.